NAPRX/CNPR Exam with 100% Correct Answers | Latest Version (2024/2025) Expert Verified, Exams of Advanced Education

Download NAPRX/CNPR Exam with 100% Correct Answers | Latest Version (2024/2025) Expert Verified and more Exams Advanced Education in PDF only on Docsity!

NAPRX/CNPR Exam with 100% Correct

Answers | Latest Version (2024/2025) Expert

Verified

1. Howiareidrugsisortediintoitherapeuticigroupsiandiclasses? firstibyitheiconditionsithatitheyiareiuseditoitreat.iandithenibyitheirimechanismsiofiaction
2. Boneimarrowitransplants. areiaitypeiofistemicellitherapy.iunlessipatient'siownicellsiareireinjected.
3. WhatidoesiAMAis tandifor?iAmericani MedicaliAssociation
4. Whatisectioniofiaidrug'sipackageiinsertidescribesisituationsiiniwhichitheidrugish ouldinotibeiusedbecauseitheirisksioutweighitheitherapeuticibenefits? contraindications 5 iWhatiisitertiaryicare? highlyispecializedimedicaliandisurgicalicareiprovidedibyiailargeimedicalicenteriforiunu sualioricomplexmedicaliproblems 6.iWhichiofitheifollowingiisiNOTioneiofitheistagesiinitheiclassiciapproachitoibrandideve lopmentistrategycoverediiniyourimanual? brandiquality 7 iWhatiareivasodilatorsiuseditoido? decreaseivasculariresistanceiandiincreaseibloodiflow
5. Whatiisitheinameiofitheiconditionithatioccursiafteriaispecificidoseiofiaidrugiisigive niatisuchiregulariintervalsithatiabsorptioniandieliminationi(andithereforeidrugiplasma iconcentration)ihaveibecomeifairlyconstant? SteadyiState
6. WhichistatementiisiTRUEiaboutioculariadm inistration?iOculariadministrationiisiusediprim

arilyitoitreatitheieye.

10. Whichientitiesiinvest'sitheimostimoneyiinipharmaceuticaliR&D? U.S.ipharmaceuticalicompanies
11. Howiareimostidrugsie xcreted?iviaitheikidneys
12. Overitheilastifewidecades,iwhatihasihappeneditoilegalilimitationsionisales'irepsidis cussionsiaboutioflabeliuses? Limitationsihaveidecreased. 14.iWhatidoesiitimeaniifitwoidrugsiareiat iparity?iBothidrugsiareiessentiallyiiniain eutraliposition. 15 iWhoiisimostilikelyitoibenefitifromielectronicisamplingiprograms?i Everyoneiwouldibenefitiequallyifromielectronicisamplingiprograms 16.iWhenireferringitoimedicationidosage,iwhichiabbreviationimeansi" one-half'SS 17 iWhatiisianiinternist? aiphysicianiwhoipracticesiinternalimedicine
13. Whichiofitheifollowingiisiaitypeiofiwhiteibl oodicell?iLymphocytes
14. WhyiareinoviceisalesirepresentativesiofteniplacediinichargeiofinegotiatingiM COiformularies?iTheyiareinot.iThisijobiisiusuallyireservediforimoreiexperienc edireps.
15. Whatidistinguishesipharmacodynamicsifromiph armacokinetics?iPharmacodynamicsistudiesitheiho witheibodyiafectsidrugs. 21 iWhatiproportioniofitheidrugsitestedionihumanisubjectsiareieventuallyiapprovedib yitheiFDA?iabouti70%
16. Accordingitoiaistudyidiscussediiniyourimanual,ihowidoimostiphysiciansipreferitoi

receiveitheiridrugsamples? directlyifromisalesirepresentatives

23. Whichiofitheifollowingiisianiexampleiofiaic entralivalue?iIibuyiAdvilitoishowithatiI'miaimo derniconsumer.
24. WhichiofitheifollowingispecialtiesilikelyihasitheiMOST emergencyicalls?icardiologist
25. Whatiafectsitheirateiofiactiveitransport? neitheritheiavailabilityioficarriersinoritheiavailabilityiofienergy
26. Overitheilastifewidecades,iwhatihasihappeneditoitheiFDAiapprovalitim eiforinewidrugs?iItihasibeenishorteneditoireduceitheicostiofinewidrugidevelo pment.
27. WhichiofitheifollowingiwouldiNOTihelpiimproveico mpliance?ipharmacistsiunderstandingihowigenericsidif erifromibrandinameidrugs
28. Whichientityichoosesiaidrug'sit radeiname?itheiFDA
29. Whatitypeiofistemicellsiareiobtainedifromiembryosiandicanidevelopiint oianyicellitype?itotipotent
30. Asitheipriceiaipatientipaysiforiaiprescriptioniincreases,iwhatihappensitoitheilik elihoodithatithepatientiwillifilliit? Itiremainsiunafectedibecauseitheiprescriptioniisineeded
31. Mostiinvoluntaryimovementsicomeifromiwhichitypeiofi muscleitissue?icardiaciandismooth
32. WhichiofitheifollowingiisiNOTioneiofitheibody'simajorior ganisystems?itheicellularisystem
33. Howidoimostidrugsiexertitheiriprimaryiphysiol

ogicaliefects?byibindingitoicellireceptorsithatiareis ensitiveitoitheiripresence

34. Whatiisitheimostireliableisourceiofiinformationiforideterminingith erapeuticallyiequivalentidrugproducts? OrangeiBook
35. Whatidoesisubcutaneousi mean?ibeneathitheiouteriskin
36. Whatishouldiaisalesirepresentativeidoiifialliofitheiprimeispacesiiniaidrugicab inetiareicoccupied?iaskistafiforipermissionitoimoveisomeiofitheiotheriproduct siinitheicabinet
37. Itiisiinappropriateiforiphysicians'iprescribingibehaviorsitoibeieducatedibyitheiripe rsonalitastesiandidiosyncrasies TRUE
38. TheiFDAidefinesiAPIiasitheiactiveiingredientiiniaidrug,iwhichiproducesitheide siredichangeiinithebody. pharmaceutical
39. Whatiareithei 2 ilegaliclassificationsiofi wholesalers?primaryiandisecondaryiwho lesaleidistributors

40. WhatitermidescribesitheiusageiofiaimedicationiforipurposesiotherithanitheiFDA- iapprovediindicationsonitheilabeling? of-labeliusage
41. Whatiisitheiacronymifori pharmacokinetics?iPK
42. Theidosageirangeiofiaidrugithatiisibothisafeiandibeneficialiisiknowniasitheithe rapeuticiwindow.True
43. WhatiisitypicallyiNOTiaicharacteristiciofiaipharmace uticalisalesirep?iPharmaceuticalisalesirepsiareinoticoncer nediabouticompetitors.
44. Whatientityigrantsidrugi patents?iTheiUSiPatentiandi TrademarkiOffice
45. Whichiofitheifollowingirefersitoialliactiveiandiinertipharmaceuticaliin gredientsiiniaidrug,includingfillersiandicolors? formulation
46. Whatiisitheidiferenceibetweenipotencyiandiefficacy? potencyirefersitoitheidrug'sistrength,iwhileiefficacyirefersitoiitsiefectiveness
47. Whatiisitheiminimumileveliofieducationirequirediforiain urseipractitioner?iaigraduateidegree
48. Howimanyinamesimustiai drugihave?iatileastithree
49. Howihasiailongeridevelopmentitimeiincreaseditheicostiofibringingiaine widrugitoimarket?iIncreasingitheicostioficapital
50. Senioricitizensiconsumeioveritimesiasimanyipharmaceuticalsiasip eopleiunderi65.three
51. Whatiagencyiregulatesitheidistributioniandiuse

ofinarcotics?iDEA

52. Whatiisipassiveidifusion? wheniaisubstanceifreelyimovesithroughiaimembraneifromiaihighiconcentrationigradien titoiailowione
53. WhatiareitheiMAINicategoriesiofidrugsiunderiFDAijurisdiction? prescriptioniandinoniprescription
54. Whatiareiallimetab olites?iproductsiofimet abolism
55. Wheniaidrugiisiadministerediorally,iwhereidoesifirst- passimetabolismioccur?iliver
56. Whatiisitheimedicalitermiforis welling?iedema
57. WhichiofitheifollowingiisiNOTipartiofitheiSeveniStepiC ascadeiofiEmotion?ibeiaiconsultant,inotiairep
58. Whichipartiofiaiclinicaliresearchipaperiisifrequentlyireferreditoiasi theiroadimap?iabstract
59. Whichiofitheifollowingiisiaimainiactiveiingredientiinilu ngisurfactants?itheophylline
60. Whatidoesiparenterali mean?iinjection
61. Whichitermidenotesiaitypeiofisubstanceithatienhancesitheiactioniofiaidr ugioriantigen?iadjunvant
62. Ifiaisalesirepresentative'siproductiisiplacedionitheiseconditieriofiaistandardithr ee-tieriformulary,iwhichiofitheifollowingiisimostilikelyitrue? Itiprobablyihasiexclusiveipreferredistatusiifiitiisinotiatiparityiwithianyiotheridrugs
63. WhichiofitheifollowingiisiNOTioneiofitheifouribasicitr ansportimechanisms?ihomeostasis

65. Whichistatementiaccuratelyidescribesiairelationshipibetweenidrugiago nistsiandiantagonists?iAgonistsiandiantagonistsicanibeiuseditogether.
66. Whatiisitheistudyiofitheiefectsiandimovementiofidrugsiinith eihumanibody?iclinicalipharmacology
67. Accordingitoiyourimanual,iwhatiisiaicommonicomplaintithatiphysiciansiha veiaboutitraditionalsamplingimethods? thatidrugisampleisupplyiisitooiunpredictable
68. Whichiofitheseientitiesiisiformedibyitwoiorimoreihospitalsioriotherihealthcareient itiesitoinegotiatereducediratesiwithiitsiaggregatedipurchasingipower? GPO
69. Whatiisianotherinameiforiaidrugiderivedifromiaibi ologicicompound?ilargeimolecule
70. Whatiisitheimosticommonipolicyiregardingipharmaceuticalirepsidi spensingidrugisamplesiinhospitals? drugisamplingiisiofteniforbidden 71 iWhichiofitheifollowingiwouldihelpiyouibuilditrustiwithiaiphysician? askingiifiheiorisheiisihavingianyiproblemsiwithitheimanagedicareicoverageiofiyouriprod ucts
71. Whatitermidenotesitheidiferenceibetweenitheiusualiefectiveidoseianditheido seithatiinducessevereiorilife-threateningisideiefects? marginiofisafety
72. Whatiareiexcipients? theiinertiingredientsiiniaidrugiformulation
73. Whatiisianotheritermiforithei AWP?listiprice
74. Whichiofitheseiisitheimostilikelyiuseiforiaiut erotoniciagent?itoiinduceilabor
75. AsiofiNovemberi2013,iwhichiofitheseicountriesihasilegalizediDTCiadvertisingiofi prescriptionidrugs?noneiofithese

77. Whyiareioralidrugsioftenitakenionianiempt yistomach?itoipassithroughitheistomachimorei quickly
78. Whatiisioneifactorithatidiferentiatesicommunityihealthicentersifr omihospitals?icommunityihealthicenteriformulariesiareimoreirestri ctive
79. Howidoesidrugisamplingiprovideiaisocialibenefit? doctorsiofteniuseidrugisamplesitoitreatipatientsiwhoiotherwiseicouldinotiafordiit
80. Whichimedicalitermidenotesitheiuseiofiaistethoscopeitoili stenitoitheiheart?iausculation
81. Whatidoientericicoatingsido? preventsidissolutioniinitheistomach
82. Whatiisitheidurationiofiexclusivityiforio rphanidrugs?i 7 iyears
83. WhatidoiNationaliAccountiMa nagersido?inegotiateicontractsiwit hiMCOiandiPBM
84. Whatidoesiitiusuallyimeaniifiaidrugirecalliisivoluntary? Theimanufacturerihasirecalleditheiproductioniitsiown.ibutinegotiatediwithitheiFDAibefo rehand.
85. Whichiphaseioficlinicalitrialsiisialsoiknowniasitheipi votaliphase?iPhaseiIII
86. Duringiwhichiphaseioficlinicalitrialsiisitheinewidrug'sisafetyiandief ectivenessifirstitestediinithetargetigroup? PhaseiII
87. Howidoiantacidsi work?byiraisingiga striciPH

88. Whatiisioneiofitheibiggestitimeiwastersiforiaip harmaceuticalisalesirep?iTraveliTime
89. Whatihappensiwheniequilibriumiisireached? equalinumbersiofimoleculesicrossitheimembraneiinibothidirections
90. Whatiareitheimosticommonivectorsiusediinig eneitherapy?iviruses
91. Whatiisitheipercentageifeeithatitheidispenseripaysitheiwholesalerifo ridistribution?iupcharge
92. Whatiisitheidiferenceibetweeniaichronici(oricontinuing)ireaction,iandiaide layedireaction?ichronicireactionsipersistiforiailongitime,idelayed reactionsitakeisomeitimeitoidevelopi 9 3 iWhatiisiclinicaliefect? theiresponseiproducedibyiaimedication
93. Whichiofitheifollowingiisianiexampleiofin oncompliance?iaipatientiforgettingitoitakeiaidr ugiatiaispecifieditimeiofiday
94. Whatiisitheiaverageicirculationitimeiofiblood? aboutiaiminute
95. Whatiisioneiwayiiniwhichipharmaceuticalisellingiisidiferentifromisellingiinimo stiotheriindustries?irepresentativeidoiNOTisellitoitheiendiuseriofitheiproduct
96. Fromiwhatitypesiofientitiesidoiprimaryiwholesaleidistributorsibuyim ostiofitheiridrugs?manufacturers
97. WhatiisitheiOfficeiofitheiInspectori Generali(01G)?ianiarmiofitheiDeptiofi HealthiandiHumaniServices
98. Whatiareidoctorsirequireditoiconsideriwhenidecidingiwhetheriorinotitoiprescribei aiparticularidrug?itheiseverityiofitheidisorderibeingitreatedianditheiefectiitihasionithei

patientsiqualityiofilife

100. Whichientityiassignsiainewidrugiitsigen ericinames?itheiUnitediStatesiAdoptediNam eiCouncil
101. Drugsicanibeiusedidaysibeyonditheirie xpirationidate.drugsinevericanibeiusedibe yondiexpirationidate
102. Whatiisinecessaryiforiaidrugitoibeiexcretediextensivelyiviaitheikidneys? Theidrugimustibeiwater-soluble,iandinotibinditooitightlyitoiproteiniinitheibloodstream
103. Whichiorganizationioriindividualiinitiatesitheiclinicalitrialiandifi nancesitheistudy?isponsor
104. Theinameidescribesitheiatomiciorimolecularis tructureiofiaidrug.chemical
105. UnderiPhRMAiCode,iisiitiacceptableioriunacceptableiforiaipharmaceuti calisalesirepitoitakeiaphysicianianditheiphysician'sispouseitoiaifundraisingidin ner? neveri(unacceptable)
106. TheiHatch-WaxmaniActiisiconsidereditheimostisignificantidrug- relatediafectingitheipharmaceuticalindustryisincei1962. legislation
107. Whatitermidenotesitheitheiextent,iquality,ioridegreeitoiwhichiaisubstanceiisipoi sonousioriharmfultoitheibody? toxicity
108. WhatiissueihasiMOSTiencouragediconsumers'idesireitoiseeimoreiO TCimedications?ilackiofiinsuranceicoverage

109. Whatiisitheidegreeitoiwhichiaimedicationiproducesiaith erapeuticiefect?iefficacy
110. Whatiisitheimostiimportantibenefitiofielectronicip rescribing?isafety
111. WhenidoesitheiFDAiregulatei genericidrugs?ialways
112. Whichiphaseiofitrialsilargelyideterminesitheic linicalidose?iPhaseiIIitrials
113. Whatiisianiadvantageiofiinactivatedivaccinesioveriatten uatedivaccines?iinactiveivaccinesihaveiaimoreistableishelfili fe
114. Whichimedicalitermidenotesiailowisupplyiofioxygenidueitoilo wibloodiflow?iischemia
115. Whatiareitheitwoimainitypesiofiprescriptionidrugim arketing?iprofessionaliphysicianipromotionsiandidire ct-to-consumeriadvertising
116. Whatiisitheisiteiofideliveryiforisubcutaneousii njections?ifattyitissueibeneathitheisurfaceiofitheisk in
117. WhatimustibeicontainediinitheiDescriptionisectioniofiaipharmaceutical ipackageiinsert?itheiproprietaryinameianditheiestablishediname
118. Whatiisitheistudyiofiaimedication'siefectsiasiititravelsith roughitheibody?ipharmacokinetics
119. Customersipurchaseiproductsifromipeopleitheyilike,itrust,iandirespect.iT hisiisicalledithelikeabilityifactor

120. Whatiisipenicillin'siprimaryimechanis miofiaction?iitidisturbsibacterialicelliwallis ynthesis
121. Accordingitoiyourimanual,ihowihasitheiU.S.ihealthcareimarketplaceic hangediinitheilastifewdecades? managedicareihasibeeniincreasinglyireplacedibyimoreipatienticenterediapproaches
122. Howidoesipharmaceuticalimarketingihelpinarrowitheitr eatmentigap?iitiencouragesipatientsitoitakeimoreiactiveirol esiinitheirihealthcare
123. Whatidoiimmunosuppressivei agentsido?ireduceiriskiofirejectionio fiforeignibodies
124. WhatitypesiofidrugsiareiEGFRii nhibitors?iantineoplastics
125. Whichiofitheifollowingimeansioutsideiofitheili vingibody?iexivivo
126. TheiFDAirequirementsiforinutraceuticalsiandimedicinaliherbsiareijustias istringentiasiforpharmaceuticals. False
127. Whatiisitheiestimatedinetigainiofiprivate- sectorihealthcare'sicontributionsitoiincreasediU.S.ilifeexpectancy? 2 - 5 itrillion
128. WhichistatementiisiTRUEiregardingipost- approvalidrugimonitoring?itheiFDAicanichooseitoiwithdr awitheiriapprovaliifinewievidenceiarises
129. Whichitermidenotesiwhenitoleranceitoioneimedicationicausesiincreasedito leranceitoianothermedication? crossitolerance

130. Patentsiexpireyearsifromitheidateiofif iling.twenty
131. Afteriaitrade- nameidrug'sipatentiexpires,ihowimayigenericiversionsiofiitibeisol d?ionlyiunderitheibrandedigenericiname
132. Whatiisirequirediforiainewipharmaceuticalitoibeiconsiderediaiviableitherapy? itiisimoreiefective,icausesifeweriseriousiadverseiefectsithaniotheridrugsionitheimarket
133. UnderitheiAMAiguidelines,iwhoiisiultimatelyiresponsibleiforiminimizingico nflictsiofiinterest?idoctors
134. Theiactiofidispensingiaipharmaceuticalialternativeiforitheip roductiprescribediispharmaceuticalisubstitution
135. Whatidoesiitimeaniifiaidrugiisisaiditoihaveiaiwideimarg iniofisafety?ithereiisiailowerichanceiofisevereiorilifeithreate ningisideiefects
136. Whichiofitheifollowingiisitheicorrectimedicaliacronymiforiefectiveidose? ED
137. Whyiisioneigroupiofisubjectsigivenianiactiveidrug,iwhileianotherigroupionlyirec eivesiaiplacebo?itoiassessitheidrugsiefectiveness
138. Aigenericiversioniisilikelyitoihaveisomeiinactiveiingredientsithatiareidif erentifromithoseiofitheoriginalidrug. True
139. Whichiofitheifollowingiisianiexampleiofiaifun ctionalivalue?iIidrinkicocoicolaibecauseiIilikeitheita ste
140. Whereiareimostidrugsi metabolized?iliver
141. Whatiisiessentialitoitheiethicalirequirementithatisubjectsibeise

lectedifairly?isubjectsishouldibeiselectedibasedioniscientificiobje ctives

142. Whichiofitheifollowingiisitheimostiappropriateisalutationiforiaicoveriletteriifi youicannotifindiacontactiname? DeariSirioriMadam
143. Whatiisipartiofibecomingianiindispensableip harmaceuticalisalesirep?iaskingiforifeedback
144. WhichiofitheifollowingiisiNOTitypicallyiincludediinitheiindicationsiandiusageise ctioniofitheipackageinsertiinformation? theidrugsiactiveimetabolites
145. Whichitermidenotesitheipracticeioficlassifyingiphysiciansiandiotherip otentialiprescribersibyanticipatediprescriptionivolume? deciling
146. Whatimakesiaidrugieligibleiforifastitrackiapprovalifr omitheiFDA?iititreatsipatientsiwithiaiseriousilife- ithreateningicondition
147. Initheigastrointestinalitract,ihelpibreakiupitabletsitoiensureifullireleaseiofitheiact iveipharmaceuticalingredient. disintegrants
148. Accordingitoiyourimanual,iwhatidoesitheiPDRPido? itilimitsisalesirepsiabilitiesitoiseeiindividualiphysiciansiprescribingidata

149. Whatiareitheicomponentsiofitheicentralin ervousisystem?itheibrainiandispinalicord
150. Whichitermidenotesitheioriginioricauseiofiaim edicalicondition?ietiology
151. PatientsidiagnosediwithiTypei 1 i diabeteshaveianiautoimmuneidiseas e
152. WhichiDTCipharmaceuticalimarketingitacticiisipermittediiniE uropeanicountries?diseaseistateiads
153. WhatiisioneiwayiiniwhichipsychologistsiDIFFERifro mipsychiatrists?ipsycologistidealiwithiemotionalithaniphy sicaliissues
154. WhatiareiPBMs? organizationsithatinegotiateibetweenipharmaceuticalicompaniesiandilargeidrugipurcha sers
155. HowidoesitheiHatch-WaxmaniActiprotectiresearch- basedidrugimanufacturers?ibyiprovidingiai 30 imonthicoolingiofiperi od
156. Whatiisitheiprocessiofiadjustingidrugidosesitoiachieveitheimaximumipo sitiveitherapeuticiefectswhileiminimizingiadverseiorisideiefects? titration
157. Whichiofitheifollowingiisistudiedimoreiinipharmacodynamicsithaniiniph armacokinetics?itheitransportationiofitheidrugitoitheispecificisiteiforidrugir eceptoriinteractions
158. HowidoesitheihealthyihumaniimmuneisystemiuseiMHCimarkers? substancesiwithoutiMHCimarkersiareidiscernediasiforeignianditargetediforidestruction
159. Whatiisiaibehind-the-counteridrug?

aniOTCidrugithatimustibeicloselyimonitoredibyitheipharmacist

160. WhenidoiMSLsimeetiwithicli nicians?iatinearlyianyistageiofithei productsilifeicycle